SFX-01 **t**reatment for **Acute Respiratory Infections** (STAR-Covid19)

Eligibility

Assessing eligibility

- Patients with community acquired pneumonia suspected to be caused by COVID-19 disease identified
- Patient lists from clinical team
- Check inclusion/exclusion via electronic or paper medical records
- Likely that assessments to determine eligibility will be carried out by the clinical team/routine care
- Investigations/assessments carried out within previous 72 hours – use the most recent result
- Where not available research team request/collect samples after obtaining informed consent
- Where any result/finding is outwith inclusion/exclusion criteria the participant is not eligible and will not be randomised.
- Screening done by a delegated & named member of the trial team
- Eligibility must be confirmed by a delegated medical doctor in the medical record

Inclusion criteria

- 18 years of age or older
- Community acquired pneumonia (defined as a new radiographic infiltrate on chest x-ray or CT scan in a patient presenting with respiratory symptoms both of which are clinically evident less than 48 hours after hospitalization).
- Tested for suspected SARS-CoV-2 infection via RT-PCR or another approved laboratory method*
- Increased risk of mortality on admission (defined by CURB65 score greater than or equal to 1 or the presence of bilateral radiographic infiltrates)
- Treatment can be commenced within 96 hours of hospital admission
- Requires hospitalisation but NOT requiring mechanical ventilation at randomisation
- Participant (or legally authorized representative) provides written informed consent
- Able to take oral medication at randomisation
- Participant (or legally authorised representative) understands and agrees to comply with planned trial procedures.

*for the avoidance of doubt, this trial permits inclusion of patients presenting with acute respiratory infections whether or not the test for SARS-CoV-2 is positive. Patients can be randomised to the study while awaiting the results of the test for SARS-CoV-2.

Inclusion criteria

CURB65 score:

SYMPTOM	POINTS
C= confusion (Abbreviated mental test score less than 8 or clinically diagnosed delirium),	1
U= blood urea greater than7mmol/L	1
R= respiratory rate greater than 30 breaths/min	1
B= blood pressure, systolic less than 90mmHg and/or diastolic blood pressure less than 60mmHg	1
Age greater than or equal to **65** years	1

- To be eligible the patient must score 1 or above

Exclusion criteria

- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than 5 times the upper limit of normal, result within 72 hours of randomisation (the result closest to randomisation should be used if several results are available and local lab ranges apply).
- Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR less than 30), result within 72 hours of randomisation (the result closest to randomisation should be used if several results are available)
- Pregnant or breast feeding.
- Anticipated transfer to another hospital which is not a trial site within 24 hours.
- Hospital-acquired pneumonia (defined as onset of respiratory illness more than 48 hours after admission to hospital)
- Allergy to SFX-01
- Patients in whom active treatment is not considered appropriate.
- Use of any investigational drug within five times of the elimination half-life after the last trial dose or within 30 days, whichever is longer

Pregnancy testing and contraception

- Women of child-bearing potential must be willing to have pregnancy testing (urine or blood) prior to randomisation- this should be done following informed consent.
- Women of childbearing potential and men who are sexually active with a woman of child bearing potential must be willing to use 2 highly effective methods of contraception):

  -combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
    oral
    intravaginal
    transdermal
  -progestogen-only hormonal contraception associated with inhibition of ovulation:
    oral
    injectable
    implantable
  -intrauterine device (IUD)
  -intrauterine hormone-releasing system (IUS)
  -bilateral tubal occlusion
  -vasectomised partner
  -sexual abstinence
- Females must use such contraception while they take the trial capsules and for 30 days afterwards. Males must use such contraception while they take the trial capsules and for 90 days afterwards.

Co-enrolment

- Participants **must not be** co-enrolled in any other CTIMP
- Participants **may be** co-enrolled in observational trials